查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387441

磊晶藥物和診斷技術市場報告：2030 年趨勢、預測和競爭分析

Epigenetic Drug and Diagnostic Technology Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

磊晶藥物與診斷技術的趨勢與預測

至2030年，全球磊晶藥物和診斷技術市場預計將達到277億美元，2024年至2030年的年複合成長率為19.2%。該市場的主要驅動力是癌症和神經系統疾病等慢性病盛行率的上升、人口老化的迅速加劇以及新磊晶藥物和診斷技術的創新。全球磊晶醫學和診斷技術市場的未來充滿希望，腫瘤學和非腫瘤學市場充滿機會。

磊晶藥物和診斷技術市場洞察

Lucintel 預計 DNMT 由於其廣泛的可用性，在預測期內仍將是一個更大的細分市場。

在這個市場中，由於癌症的高成長和癌症死亡人數的增加，腫瘤學將繼續成為較大的細分市場。

由於擁有成熟的醫療設施和快速成長的老年人口，北美在預測期內可能仍然是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球磊晶藥物與診斷技術市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球磊晶醫學和診斷技術市場趨勢（2018-2023）和預測（2024-2030）
  • 按治療類型分類的全球磊晶藥物和診斷技術市場
    • HDAC
    • DNMT
  • 按技術分類的全球磊晶醫學和診斷技術市場
    • DNA甲基化
    • 組蛋白甲基化
    • 組蛋白乙醯化
    • 大非編碼RNA
    • 微小RNA的修飾
    • 染色質結構
  • 全球磊晶醫學和診斷技術市場（按應用）
    • 腫瘤學
    • 非腫瘤學

第4章 2018-2030年分地區市場趨勢及預測分析

  • 按地區分類的全球磊晶藥物和診斷技術市場
  • 北美磊晶藥物與診斷技術市場
  • 歐洲磊晶醫學與診斷技術市場
  • 亞太磊晶醫學與診斷技術市場
  • 其他區域磊晶藥物和診斷技術市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球磊晶藥物和診斷技術市場成長機會（按治療類型）
    • 按技術分類的全球磊晶藥物和診斷技術市場的成長機會
    • 全球磊晶藥物和診斷技術市場的成長機會（按應用）
    • 全球磊晶藥物和診斷技術市場成長機會（按地區）
  • 全球磊晶醫學及診斷技術市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球磊晶醫學和診斷技術市場的容量
    • 全球磊晶醫學和診斷技術市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Eisai
  • Novartis
  • Illumina
  • Merck Sharp & Dohme
  • Qiagen
簡介目錄

Epigenetic Drug and Diagnostic Technology Trends and Forecast

The future of the global epigenetic drug and diagnostic technology market looks promising with opportunities in the oncology and non-oncology markets. The global epigenetic drug and diagnostic technology market is expected to reach an estimated $27.7 billion by 2030 with a CAGR of 19.2% from 2024 to 2030. The major drivers for this market are rising prevalence of chronic diseases like cancer and neurological disorders, surge in geriatric population, and innovations of new epigenetic drugs and diagnostics technologies.

A more than 150-page report is developed to help in your business decisions.

Epigenetic Drug and Diagnostic Technology by Segment

The study includes a forecast for the global epigenetic drug and diagnostic technology by type of therapy, technology, application, and region.

Epigenetic Drug and Diagnostic Technology Market by Type of Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • HDAC
  • DNMT

Epigenetic Drug and Diagnostic Technology Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • DNA Methylation
  • Histone Methylation
  • Histone Acetylation
  • Large Noncoding RNA
  • Microrna Modification
  • Chromatin Structures

Epigenetic Drug and Diagnostic Technology Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Non-Oncology

Epigenetic Drug and Diagnostic Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Epigenetic Drug and Diagnostic Technology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies epigenetic drug and diagnostic technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the epigenetic drug and diagnostic technology companies profiled in this report include-

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Eisai
  • Novartis
  • Illumina
  • Merck Sharp & Dohme
  • Qiagen

Epigenetic Drug and Diagnostic Technology Market Insights

Lucintel forecasts that DNMT will remain the larger segment over the forecast period due to wide-scale availability.

Within this market, oncology will remain the larger segment due to high growth of cancer and rising number of deaths caused by cancer.

North America will remain the largest region over the forecast period due to presence of well established healthcare facilities and surge in geriatric population in the region.

Features of the Global Epigenetic Drug and Diagnostic Technology Market

Market Size Estimates: Epigenetic drug and diagnostic technology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Epigenetic drug and diagnostic technology market size by type of therapy, technology, application, and region in terms of value ($B).

Regional Analysis: Epigenetic drug and diagnostic technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type of therapy, technologies, applications, and regions for the epigenetic drug and diagnostic technology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the epigenetic drug and diagnostic technology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the epigenetic drug and diagnostic technology market size?

Answer: The global epigenetic drug and diagnostic technology market is expected to reach an estimated $27.7 billion by 2030.

Q2. What is the growth forecast for epigenetic drug and diagnostic technology market?

Answer: The global epigenetic drug and diagnostic technology market is expected to grow with a CAGR of 19.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the epigenetic drug and diagnostic technology market?

Answer: The major drivers for this market are rising prevalence of chronic diseases like cancer and neurological disorders, surge in geriatric population, and innovations of new epigenetic drugs and diagnostics technologies.

Q4. What are the major segments for epigenetic drug and diagnostic technology market?

Answer: The future of the epigenetic drug and diagnostic technology market looks promising with opportunities in the oncology and non-oncology markets.

Q5. Who are the key epigenetic drug and diagnostic technology market companies?

Answer: Some of the key epigenetic drug and diagnostic technology companies are as follows:

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Eisai
  • Novartis
  • Illumina
  • Merck Sharp & Dohme
  • Qiagen

Q6. Which epigenetic drug and diagnostic technology market segment will be the largest in future?

Answer: Lucintel forecasts that DNMT will remain the larger segment over the forecast period due to wide-scale availability.

Q7. In epigenetic drug and diagnostic technology market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to presence of well established healthcare facilities and surge in geriatric population in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the epigenetic drug and diagnostic technology market by type of therapy (HDAC and DNMT), technology (DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microrna modification, and chromatin structures), application (oncology and non-oncology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Epigenetic Drug and Diagnostic Technology Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Epigenetic Drug and Diagnostic Technology Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Epigenetic Drug and Diagnostic Technology Market by Type of Therapy
    • 3.3.1: HDAC
    • 3.3.2: DNMT
  • 3.4: Global Epigenetic Drug and Diagnostic Technology Market by Technology
    • 3.4.1: DNA Methylation
    • 3.4.2: Histone Methylation
    • 3.4.3: Histone Acetylation
    • 3.4.4: Large Noncoding RNA
    • 3.4.5: Microrna Modification
    • 3.4.6: Chromatin Structures
  • 3.5: Global Epigenetic Drug and Diagnostic Technology Market by Application
    • 3.5.1: Oncology
    • 3.5.2: Non-oncology

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Epigenetic Drug and Diagnostic Technology Market by Region
  • 4.2: North American Epigenetic Drug and Diagnostic Technology Market
    • 4.2.2: North American Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
  • 4.3: European Epigenetic Drug and Diagnostic Technology Market
    • 4.3.1: European Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
    • 4.3.2: European Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
  • 4.4: APAC Epigenetic Drug and Diagnostic Technology Market
    • 4.4.1: APAC Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
    • 4.4.2: APAC Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
  • 4.5: ROW Epigenetic Drug and Diagnostic Technology Market
    • 4.5.1: ROW Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
    • 4.5.2: ROW Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Type of Therapy
    • 6.1.2: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Technology
    • 6.1.3: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Application
    • 6.1.4: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Region
  • 6.2: Emerging Trends in the Global Epigenetic Drug and Diagnostic Technology Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Epigenetic Drug and Diagnostic Technology Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Epigenetic Drug and Diagnostic Technology Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Roche Diagnostics
  • 7.2: Thermo Fisher Scientific
  • 7.3: Eisai
  • 7.4: Novartis
  • 7.5: Illumina
  • 7.6: Merck Sharp & Dohme
  • 7.7: Qiagen